{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:15:41Z","timestamp":1789600541269,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Over the past decades, genetic and observational evidence has positioned lipoprotein(a) as novel important and independent risk factor for cardiovascular disease (ASCVD) and aortic valve stenosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>As Lp(a) levels are determined genetically, lifestyle interventions have no effect on Lp(a)-mediated ASCVD risk. While traditional low-density lipoprotein cholesterol (LDL-C) can now be effectively lowered in the vast majority of patients, current lipid lowering therapies have no clinically relevant Lp(a) lowering effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>\n                      There are multiple Lp(a)-directed therapies in clinical development targeting\n                      <jats:italic>LPA<\/jats:italic>\n                      mRNA that have shown to lower Lp(a) plasma levels for up to 90%: pelacarsen, olpasiran, and SLN360. Pelacarsen is currently investigated in a phase 3 cardiovascular outcome trial expected to finish in 2024, while olpasiran is about to proceed to phase 3 and SLN360\u2019s phase 1 outcomes were recently published. If proven efficacious, Lp(a) will soon become the next pathway to target in ASCVD risk management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-022-01060-4","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T07:08:56Z","timestamp":1662448136000},"page":"831-838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Lp(a): a New Pathway to Target?"],"prefix":"10.1007","volume":"24","author":[{"given":"Nick S.","family":"Nurmohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Kraaijenhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S. G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"1060_CR1","first-page":"230","volume":"6","author":"K Berg","year":"1974","unstructured":"Berg K, Dahl\u00e9n G, Frick MH. Lp(a) lipoprotein and pre-\u03b21-lipoprotein in patients with coronary heart disease. Clin Genet John Wiley & Sons, Ltd. 1974;6:230\u20135.","journal-title":"Clin Genet John Wiley & Sons, Ltd"},{"key":"1060_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69:692\u2013711.","journal-title":"J Am Coll Cardiol"},{"key":"1060_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","volume":"79","author":"A Mehta","year":"2022","unstructured":"Mehta A, Vasquez N, Ayers CR, Patel J, Hooda A, Khera A, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol Am College Cardiol Foundation. 2022;79:757\u201368.","journal-title":"J Am Coll Cardiol Am College Cardiol Foundation"},{"key":"1060_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"\u2022 Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. 2018 Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3:619\u201327 This mendelian randomization used 43 genetic variants in the LPA gene region to determine the genetically predicted lowering Lp(a) effects on ASCVD. A 10-mg\/dL lower predicted Lp(a) concentration was associated with a 5.8% lower ASCVD risk. Moreover, to match the ASCVD risk benefit from 1 mmol\/l (38.67 mg\/dl) LDL-C lowering, an estimated 102 mg\/dl (213 nmol\/l) reduction in Lp(a) will be needed.","journal-title":"JAMA Cardiol"},{"key":"1060_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","volume":"302","author":"RW Tipping","year":"2009","unstructured":"Tipping RW, Ford CE, Simpson LM, Walldius G, Jungner I, Folsom AR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA - J Am Med Assoc. 2009;302:412\u201323.","journal-title":"JAMA - J Am Med Assoc"},{"key":"1060_CR6","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844\u201353.","journal-title":"Eur Heart J"},{"key":"1060_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","volume":"74","author":"A Langsted","year":"2019","unstructured":"Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. Am College Cardiol Foundation. 2019;74:54\u201366.","journal-title":"Am College Cardiol Foundation"},{"key":"1060_CR8","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA - J Am Med Assoc. 2009;301:2331\u20139.","journal-title":"JAMA - J Am Med Assoc"},{"key":"1060_CR9","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","volume":"40","author":"A Langsted","year":"2019","unstructured":"Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40:2760\u201370.","journal-title":"Eur Heart J"},{"key":"1060_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. Am College Cardiol Foundation. 2014;63:470\u20137.","journal-title":"Am College Cardiol Foundation"},{"key":"1060_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","volume":"16","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2019;16:305\u201318.","journal-title":"Nat Rev Cardiol"},{"key":"1060_CR12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","volume":"60","author":"A Helgadottir","year":"2012","unstructured":"Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60:722\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1060_CR13","first-page":"1953","volume":"57","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. J Lipid Res Am Soc Biochem Mole Biol. 2016;57:1953\u201375.","journal-title":"J Lipid Res Am Soc Biochem Mole Biol"},{"key":"1060_CR14","unstructured":"Maio S Di, Lamina C, Coassin S, Forer L, W\u00fcrzner R, Sch\u00f6nherr S, et al. Lipoprotein(a) and SARS-CoV-2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events. J Intern Med. John Wiley & Sons, Ltd; 2021;n\/a."},{"key":"1060_CR15","doi-asserted-by":"crossref","unstructured":"Gencer B, Kronenberg F, Stroes ES, Mach F. Lipoprotein(a): the revenant. Eur. Heart J. Oxford University Press; 2017;1553\u201360.","DOI":"10.1093\/eurheartj\/ehx033"},{"key":"1060_CR16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1373\/clinchem.2019.306738","volume":"65","author":"DC Chan","year":"2019","unstructured":"Chan DC, Pang J, Hooper AJ, Bell DA, Burnett JR, Watts GF. Effect of lipoprotein(a) on the diagnosis of familial hypercholesterolemia: does it make a difference in the clinic? Clin Chem. 2019;65:1258\u201366.","journal-title":"Clin Chem"},{"key":"1060_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","volume":"4","author":"A Langsted","year":"2016","unstructured":"Langsted A, Kamstrup PR, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol Elsevier. 2016;4:577\u201387.","journal-title":"Lancet Diabetes Endocrinol Elsevier"},{"key":"1060_CR18","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehaa1050","volume":"42","author":"T Speer","year":"2021","unstructured":"Speer T, Ridker PM, Von Eckardstein A, Schunk SJ, Fliser D. Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J. 2021;42:2170\u201385.","journal-title":"Eur Heart J"},{"key":"1060_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0114397","volume":"9","author":"J Lin","year":"2014","unstructured":"Lin J, Reilly MP, Terembula K, Wilson FP. Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS ONE. 2014;9:1\u201316.","journal-title":"PLoS ONE"},{"key":"1060_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0022-2275(20)37150-9","volume":"38","author":"F Kronenberg","year":"1997","unstructured":"Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, et al. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res. 1997;38:1755\u201363.","journal-title":"J Lipid Res"},{"key":"1060_CR21","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/sj.ki.5002131","volume":"71","author":"ME Frischmann","year":"2007","unstructured":"Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int Elsevier Masson SAS. 2007;71:1036\u201343.","journal-title":"Kidney Int Elsevier Masson SAS"},{"key":"1060_CR22","doi-asserted-by":"crossref","unstructured":"Kostner KM, Kostner GM 2017 Lipoprotein (a): a historical appraisal. J Lipid Res. \u00c2\u00a9 THE AUTHORS. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology 2017;58:1\u201314.","DOI":"10.1194\/jlr.R071571"},{"key":"1060_CR23","doi-asserted-by":"crossref","unstructured":"Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagstr\u00f6m E, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. 2022;ehac056.","DOI":"10.1093\/eurheartj\/ehac056"},{"key":"1060_CR24","doi-asserted-by":"crossref","unstructured":"Nurmohamed NS, Kaiser Y, Schuitema PCE, Ibrahim S, Nierman M, Fischer JC, et al. Finding very high lipoprotein(a): the need for routine assessment. Eur J Prev Cardiol. 2021;","DOI":"10.1093\/eurjpc\/zwab167"},{"key":"1060_CR25","first-page":"635","volume":"129","author":"AV Khera","year":"2014","unstructured":"Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk. Circ Am Heart Assoc. 2014;129:635\u201342.","journal-title":"Circ Am Heart Assoc"},{"key":"1060_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","volume":"40","author":"CM Madsen","year":"2020","unstructured":"Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg\/dL (105 nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol Am Heart Assoc. 2020;40:255\u201366.","journal-title":"Arterioscler Thromb Vasc Biol Am Heart Assoc"},{"key":"1060_CR27","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41:2275\u201384.","journal-title":"Eur Heart J"},{"key":"1060_CR28","doi-asserted-by":"crossref","unstructured":"de Boer LM, Oorthuys AOJ, Wiegman A, Langendam MW, Kroon J, Spijker R, et al. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2021;zwab171.","DOI":"10.1016\/j.atherosclerosis.2022.06.202"},{"key":"1060_CR29","doi-asserted-by":"publisher","first-page":"17887","DOI":"10.1038\/s41598-018-36204-7","volume":"8","author":"A Sahebkar","year":"2018","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Pirro M, Banach M, Watts GF, Sirtori C, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2018;8:17887.","journal-title":"Sci Rep"},{"key":"1060_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","volume":"78","author":"K Awad","year":"2018","unstructured":"Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M, Group on behalf of L and BPM-AC (LBPMC). Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Drugs. 2018;78:453\u201362.","journal-title":"Drugs."},{"key":"1060_CR31","first-page":"229","volume":"6","author":"BR Jaeger","year":"2009","unstructured":"Jaeger BR, Richter Y, Nagel D, Heigl F, Vogt A, Roeseler E, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med. 2009;6:229\u201339.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"1060_CR32","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","volume":"13","author":"PM Moriarty","year":"2019","unstructured":"Moriarty PM, Gray JV, Gorby LK. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease. J Clin Lipidol. 2019;13:894\u2013900.","journal-title":"J Clin Lipidol"},{"key":"1060_CR33","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","volume":"77","author":"NS Nurmohamed","year":"2021","unstructured":"Nurmohamed NS, Navar AM, Kastelein JJP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC Focus Seminar 1\/4. J Am Coll Cardiol Am College Cardiol Foundation. 2021;77:1564\u201375.","journal-title":"J Am Coll Cardiol Am College Cardiol Foundation"},{"key":"1060_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","volume":"15","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Kelly SE, McKenney JM, Lalwani ND. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: a randomized, controlled trial. J Clin Lipidol. 2021;15:593\u2013601.","journal-title":"J Clin Lipidol"},{"key":"1060_CR35","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med Massachusetts Med Soc. 2017;376:1713\u201322.","journal-title":"N Engl J Med Massachusetts Med Soc"},{"key":"1060_CR36","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med Massachusetts Medical Society. 2018;379:2097\u2013107.","journal-title":"N Engl J Med Massachusetts Medical Society"},{"key":"1060_CR37","first-page":"1600","volume":"0","author":"NA Marston","year":"2020","unstructured":"Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, et al. The effect of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibition on the risk of venous thromboembolism. Circulation Am Heart Assoc. 2020;0:1600\u20137.","journal-title":"Circulation Am Heart Assoc"},{"key":"1060_CR38","first-page":"1483","volume":"139","author":"ML O'Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Sergio F, Giugliano RP, Stroes ESG, Estella K, Ioanna G-B, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circ Am Heart Assoc. 2019;139:1483\u201392.","journal-title":"Circ Am Heart Assoc"},{"key":"1060_CR39","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","volume":"41","author":"M Szarek","year":"2020","unstructured":"Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41:4245\u201355.","journal-title":"Eur Heart J"},{"key":"1060_CR40","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med Massachusetts Med Soc. 2017;376:1430\u201340.","journal-title":"N Engl J Med Massachusetts Med Soc"},{"key":"1060_CR41","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med Massachusetts Med Soc. 2020;382:1520\u201330.","journal-title":"N Engl J Med Massachusetts Med Soc"},{"key":"1060_CR42","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med Massachusetts Med Soc. 2020;382:1507\u201319.","journal-title":"N Engl J Med Massachusetts Med Soc"},{"key":"1060_CR43","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet Elsevier Ltd. 2016;388:2239\u201353.","journal-title":"Lancet Elsevier Ltd"},{"key":"1060_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"\u2022 Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med Massachusetts Med Soc. 2020;382:244\u201355. This phase-2b randomized, double-blind, placebo-controlled, dose-ranging trial with pelacarsen showed up to 80% reduction in Lp(a) plasma levels after 6 months of treatment with no safety concerns.","journal-title":"N Engl J Med Massachusetts Med Soc"},{"key":"1060_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","volume":"28","author":"MJ Koren","year":"2022","unstructured":"\u2022 Koren MJ, Moriarty PM, Baum SJ, Neutel J, Hernandez-Illas M, Weintraub HS, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28:96\u2013103. Findings of the phase 1 dose-escalation trial with siRNA olpasiran showed 97% reduction in Lp(a) levels without any serious adverse events in 64 individuals.","journal-title":"Nat Med"},{"key":"1060_CR46","unstructured":"\u2022 Nissen SE, Wolski K, Balog C, Swerdlow DI, Scrimgeour AC, Rambaran C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. Jama. 2022; The first results of phase 1 SLN360 trial demonstrated a dose-dependent reduction up to 98% in Lp(a) plasma levels in 32 participants. Administration of the siRNA was well tolerated."},{"key":"1060_CR47","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","volume":"48","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"1060_CR48","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"1060_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251\u201361.","journal-title":"Atherosclerosis"},{"key":"1060_CR50","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LAT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med Massachusetts Med Soc. 2019;380:1022\u201332.","journal-title":"N Engl J Med Massachusetts Med Soc"},{"key":"1060_CR51","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LAT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial. JAMA - J Am Med Assoc. 2019;322:1780\u20138.","journal-title":"JAMA - J Am Med Assoc"},{"key":"1060_CR52","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LAT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc American Heart Association. 2019;8:e011662.","journal-title":"J Am Heart Assoc American Heart Association"},{"key":"1060_CR53","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","volume":"79","author":"C Yeang","year":"2022","unstructured":"Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, et al. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79:1035\u201346.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-022-01060-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01060-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T22:14:12Z","timestamp":1665008052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-022-01060-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1060"],"URL":"https:\/\/doi.org\/10.1007\/s11883-022-01060-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"7 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NN is co-founder of Lipid Tools. ESGS reports advisory board\/lecturing fees paid to the institution of ESGS by Amgen, Novartis, Sanofi, Regeneron, Esperion, and IONIS. JMK has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}